Search

Liposomes decorated with tumour-targeting cell-penetrating peptides can enhance specific drug delivery at the tumour site. The TR peptide, c(RGDfK)-AGYLLGHINLHHLAHL(Aib)HHIL, is pH-sensitive and actively targets tumour cells that overexpress integrin receptor α v β 3 , such as B16F10 melanoma cells. Liposomes can be modified with the TR peptide by two different methods: utilization of the cysteine residue on TR to link DSPE-PEG2000-Mal contained in the liposome formula (LIP TR ) or decoration of TR with a C18 stearyl chain (C18-TR) for direct insertion into the liposomal phospholipid bilayer through electrostatic and hydrophobic interactions (LIP C18-TR ). We found that both TR and C18-TR effectively reversed the surface charge of the liposomes when the systems encountered the low pH of the tumour microenvironment, but LIP C18-TR exhibited a greater increase in the charge, which led to higher cellular uptake efficiency. Correspondingly, the IC 50 values of PTX-LIP TR and PTX-LIP C18-TR in B16F10 cells in vitro were 2.1-fold and 2.5-fold lower than that of the unmodified PTX-loaded liposomes (PTX-LIP), respectively, in an acidic microenvironment (pH 6.3). In B16F10 tumour-bearing mice, intravenous administration of PTX-LIP TR and PTX-LIP C18-TR (8 mg/kg PTX every other day for a total of 4 injections) caused tumour reduction ratios of 39.4% and 56.1%, respectively, compared to 20.8% after PTX-LIP administration. Thus, we demonstrated that TR peptide modification could improve the antitumour efficiency of liposomal delivery systems, with C18-TR presenting significantly better results. After investigating different modification methods, our data show that selecting an adequate method is vital even when the same molecule is used for decoration., (© 2022. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.)

Objective: To prepare encapsulated clopidogrel bisulfate (CLP) liposomes so as to deal with the poor water solubility of CLP, and to provide the experimental basis for the development of CLP formulations for intravascular injection., Methods: CLP-loaded liposomes were prepared using thin film hydration/sonication method and pH gradient active drug loading technology. Then, the morphology, particle size, encapsulation efficiency, drug loading capacity, Zeta potentials and in vitro release behavior were characterized. Bilateral renal arteries of Sprague-Dawley (SD) rats were clamped with micro-artery clamps to establish the model of renal ischemia-reperfusion injury (IRI) in male SD rats. The study aimed to preliminarily investigate the therapeutic effect of CLP-loaded liposome pretreatment on renal IRI in rats., Results: It was found that the optimal formulation and preparation technology of CLP liposomes were as follows: the CLP-to-phospholipid weight ratio of 1∶10, phospholipid-to-cholesterol ratio of 6∶1, octadecylamine-to-CLP ratio of 1.2∶1, PEG 400 -to-CLP ratio of 1∶1, and incubation at 50 ℃ for 40 min. Then, following ultrasonication of 100 W efficiency at 5-second intervals for 20 times, CLP loading was conducted using 5 mL of 0.1 mol/L citric acid buffer at pH 3.0. Liposome samples were prepared with the film dispersion method, and the pH value was adjusted to 7.5 through pH gradient active drug loading technology. The CLP-loaded liposomes obtained in this way had a rounded shape, good dispersity, an average particle size of (134.13±2.60) nm, polydispersity index (PDI) of 0.25±0.02, and a Zeta potential of (2.12±0.23) mV. The encapsulation efficiency was found to be (98.66±0.14)%, and the drug loading capacity was (7.47±0.01)%. The in vitro release results showed that 66.24% of CLP was released cumulatively within 72 h. Preliminary efficacy experiments showed that animals pretreated with CLP-loaded liposomes had lower serum levels of blood urea nitrogen and creatinine compared to the levels of IRI model rats without any pretreatment., Conclusion: CLP-loaded liposomes were successfully prepared, which might provide the experimental foundation for the future development of CLP formulations for injection., (Copyright© by Editorial Board of Journal of Sichuan University (Medical Sciences).)

The transformersome is a new kind of lipoid drug delivery carrier. It has a number of excellent properties, including deformability, pressure permeability, and amphiphilicity. It has been widely used in the field of percutaneous and oral administration of medication. However, due to factors concerning its formulation, the stability and effectiveness of intravenous injection and other systemic routes of administration of transfersomes should be carefully examined. As an alternative, the formulation can be enhanced or improved in order to better exploit the strengths and avoid the weaknesses. Because of its deformability, transfersome may have distinctive potential strengths in the penetration of physiological barriers, for example, the blood-brain barrier, and in the research and development of transdermal immunization vaccines. This review has summarized five aspects of transfersomes, including the main properties, the formulation and process influencing factors, evaluation methods, main administration routes, and problems. Herein, we have given some examples and analysis, summarized the research achievements and assessd prospects for future development., (Copyright© by Editorial Board of Journal of Sichuan University (Medical Sciences).)

Gemcitabine (Gem) is a standard first-line treatment for pancreatic cancer (PC). However, its chemotherapeutic efficacy is hampered by various limitations such as short half-life, metabolic inactivation, and lack of tumor localizing. We previously synthesized a lipophilic Gem derivative (Gem formyl hexadecyl ester, GemC16) that exhibited improved antitumor activity in vitro. In this study, a target ligand N,N-dimethyl-1,3-propanediamine was conjugated to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[hydroxyl succinimidyl (polyethylene glycol-2000)] (DSPE-PEG-NHS) to form DSPE-PEG-2N. Then, pancreas-targeting liposomes (2N-LPs) were prepared using the film dispersion-ultrasonic method. GemC16-loaded 2N-LPs displayed near-spherical shapes with an average size distribution of 157.2 nm (polydispersity index (PDI) = 0.201). The encapsulation efficiency of GemC16 was up to 97.3% with a loading capacity of 8.9%. In human PC cell line (BxPC-3) and rat pancreatic acinar cell line (AR42J), cellular uptake of 2N-LPs was significantly enhanced compared with that of unmodified PEG-LPs. 2N-LPs exhibited more potent in vitro cytotoxicity against BxPC-3 and AR42J cell lines than PEG-LPs. After systemic administration in mice, 2N-LPs remarkably increased drug distribution in the pancreas. In an orthotopic tumor mouse model of PC, GemC16-bearing liposomes were more effective in preventing tumor growth than free GemC16. Among these treatments, 2N-LPs showed the best curative effect. Together, 2N-LPs represent a promising nanocarrier to achieve pancreas-targeting drug delivery, and this work would provide new ideas for the chemotherapy of PC.

This study is to report the preparation of complexes of Ad5 and anionic liposomes (AL-Ad5), the amplification of adenoviruses with enhanced green fluorescent protein (eGFP) reporter gene performed by HEK 293 cells, the adenoviral vectors purified by cesium chloride gradient centrifugation, and the titer of adenovirus determined by cytopathic effect (CPE) method, hexon capsid immunoassay and quantitative-PCR (Q-PCR), separately. The prescription and experiment conditions were optimized by central composite design (CCD). The complexes of Ad5 and AL-Ad5 were formulated by the calcium-induced phase change method. The morpholopy, particle size and zeta potential were detected by dynamic light scattering (DLS) and transmission electron microscopy (TEM), respectively. Additionally, the bicolourable fluoresce-labeled complexes (F(labeled)-AL-Ad5) were prepared and their intracellular location in MDCK cells was detected by confocal laser scanning microscopy (CLSM). The results indicate that the complexes of AL-Ad5 exhibited a uniform distribution with a particle size of 211 +/- 10 nm and a zeta potential of -41.2 +/- 2.2 mV. The result of CLSM demonstrates that the intracellular location of red fluoresce-labeled adenovirus was consistent with that of green fluoresce-labeled liposomes suggesting that the naked adenovirus was well encapsulated by the anionic liposomes in complexes of AL-Ad5.

Background: p27(kip1) (p27), a cyclin-dependent kinase inhibitor (CDKI), is an important regulator of cell cycle progression and a putative tumor suppressor gene, and plays an important role in the inhibition of genesis and progression of several kinds of cancers. The present study aimed to evaluate the anti-tumor effects of p27 gene therapy by a nonviral gene delivery strategy on pulmonary metastatic tumors., Methods: A recombinant plasmid composed of a p27 sequence was constructed and identified; it was then formulated with condensing agent protamine sulfate and entrapped into cationic liposomes. The resulting lipid-polycation-DNA complexes (LPD) were prepared into lyophilized forms. 5 x 10(5) of CT26 colorectal adenocarcinoma cells were inoculated into female Balb/c mice via the tail vein to establish lung tumor models. On the second day, mice were randomly divided into six groups for different intravenous treatments: phosphate-buffered saline, empty liposomes, naked pDNA, LPD-p27 kip1, Cisplatin (DPP), and LPD-p27 kip1 plus DPP, respectively., Results: The growth curve of tumor and the growth inhibition rate of tumor showed that p27-LPDs could prolong the lifespan of the mice significantly, whereas the combination of p27-LPDs and DPP could further prolong the lifespan of the tumor-bearing animals. The histology of tumors examined by hematoxylin and eosin staining indicated that p27-LPDs had a stronger inhibition effect. Significant expression of p27 was detected in tumors using an immunohistochemical technique., Conclusions: Lyophilized LPD could be used as a potential in vivo gene delivery carrier for lung cancer gene therapy., ((c) 2009 John Wiley & Sons, Ltd.)

Transferrin modified pro-cationic liposomes were prepared and used to investigate the effect of targeting therapeutic genes to human hepatoma carcinoma cells in vitro. The main lipid CHETA, cholest-5-en-3beta-yl[2-[[4-[(carboxymethyl)dithio]-1-iminobutyl]amino]ethyl] carbamate (C36H61N3O4S2), was synthesized and used to prepare pro-cationic liposomes. The thymidine kinase (TK) gene loaded pro-cationic liposomes were prepared by first mixing the plasmid DNA and protamine together, and then incubating the resulted polyplexes with blank pro-cationic liposomes preformed by the thin film dispersion-sonication method. Transferrin (Tf) was adsorbed on the surface of pro-cationic liposomes via electrostatic interactions to form transferrin modified pro-cationic liposomes. Cellular association was measured by fluorimetry at excitation and emission wavelengths of 490 and 520 nm, respectively. The viability of TK gene infected cells following administration of ganciclovir (GCV) was investigated by MTT assay. The transferrin modified TK gene pro-cationic liposomes had a mean diameter of 240 +/- 12 nm and zeta potential of -24.10 +/- 2.5 mV (n = 3). The transmission electron microscopy image indicated that most of the liposomes were relatively regular and spherical with a condensed core inside. Cell-associated fluorescence of Tf-liposomes and unmodified liposomes (without transferrin) was 7.8 x 10(6), and 3.2 x 10(6) per milligram protein, respectively. Compared to Lipofectamine 2000 (Invitrogen, USA) the pro-cationic liposomes and transferrin modified pro-cationic liposomes had less cytotoxicity to cells. The transduced TK gene HepG2 cells were more sensitive to GCV than the un-transduced TK gene ones and the human normal Chang liver cells were not affected by the TK/GCV system mediated by procationic liposomes.

The procationic liposomes-protamine-DNA (PLPD) vectors we described here are non-viral vehicles for gene delivery comprised of polycation-condensed plasmid DNA and procationic liposomes made of phospholipids, cholesterol, and CHETA (Cholest-5-en-3beta-yl[2-[[4-[(carboxymethyl)dithio]-1-iminobutyl]amino]ethyl] carbamate, C36H61N3O4S2). Response surface methodology (RSM) was employed to optimize the formulation of PLPD. A three-factor, five-level RSM design was used for the optimization procedure, with the weight ratio of protamine/DNA (X1), the molar percent of CHETA (X2), and the weight ratio of CHETA/DNA (X3) in the procationic liposomes as the independent variables. PLPD size (Y1) and PLPD transfectivity (Y2) that was quantified as mU of beta-galactosidase per milligram of total protein were response variables. The simple factor experiment was utilized to define the experimental design region, and therefore the responses for the 15 formulations were obtained. Mathematical equations and response surface plots were used to relate the dependent and independent variables. The mathematical model predicted the optimized levels of X1, X2, and X3 through which the desired particle size and transfectivity were achieved. According to these levels, an optimized PLPD formulation was prepared, resulting in a particle size of 228.9 +/- 8.0 nm and transfectivity of 24.26 +/- 2.60 mU beta-galactosidase/mg protein.

We developed a novel transferrin modified non-viral gene delivery system, transferrin-modified procationic-liposome-protamine-DNA complexes (Tf-PLPD) and investigated its characteristics. Blank procationic liposomes were prepared using the film dispersion filter method. Protamine was used to condense plasmid DNA to form protamine-DNA complexes and the complexes were further incubated with blank procationic liposomes to form PLPD. Transferrin was adsorbed onto the surface of PLPD via an electrostatic interaction, and thus Tf-PLPD was produced. Characteristics such as stability in rat serum, morphology, average particle size, zeta potential, and transfection efficiency in HepG2 cells were further investigated. The results indicated that the procationic liposomes remained stable in rat serum for 24 h. Tf-PLPD protected plasmid DNA from enzymatic degradation even after lyophilization. The size distribution of Tf-PLPD was in the range of 240+/-12 nm and the zeta potential was -24.10+/-2.5 mV (n=3), respectively. The transfection efficiencies of Tf-PLPD were 24.26+/-2.6 mU beta-galactosidase/mg protein. Lyophilization and the presence of serum did not affect the transfectivity of Tf-PLPD and the procationic liposomes also had low cytotoxicity to cells.

A novel transferrin modified non-viral gene delivery system Tf-PLPD was developed and the related characteristics was investigated. Blank procationic liposomes were prepared by film dispersion-filteration method. PLPD was prepared as follows by first mixing the plasmid DNA and protamine together, then the resulted polyplexes were incubated for 10 min at room temperature, followed by addition of preformed blank procationic liposomes. Transferrin was adsorbed at the surface of PLPD via electrostatic interactions to form Tf-PLPD. Central composite design (CCD) was employed to optimize the formulation. The HepG2 cells were transfected using lacZ as reporter gene and characteristics such as the morphology, the mean particle size, the zeta potential and the transfection efficiency in HepG2 cells were further investigated by different methods. The resulting PLPD had a regular spherical surface with an average size of (228. 9 +/- 8. 0) nm (polydispersity index, PDI = 0. 122 +/- 0. 02, n = 3) , a zeta potential of ( - 25. 08 +/-2. 50) mV (n = 3) and a transfection efficiency of (12. 18 +/- 3. 80) mU x mg(-1) (protein). The Tf-PLPD had an average size of (240 +/- 12) nm (polydispersity index, PDI = 0. 150 +/- 0. 03, n = 3), a zeta potential of ( - 24. 10 +/- 2. 50) mV ( n = 3) and a transfection efficiency of (24. 26 +/- 2. 60) mU x mg(-1) (protein) , 20 times greater than that of the naked plasmid DNA. The presence of serum didn' t affect the tansfection activity of PLPD or Tf-PLPD. Compared to one kind of cationic liposomes (liposome-protamine-DNA, LPD), the PLPD and Tf-PLPD had much less cytotoxicity to three hepatic cell lines (including HepG2, SMMC7721 and Chang' s normal hepatocyte). The results indicated that the Tf-PLPD is a perspective non-viral vector for gene delivery systems.

A novel non-viral gene delivery system, Procationic-Liposome-Protamine-DNA complexes (PLPD) which could further adsorb transferrin on the surface as a targeting ligand to form Tf-PLPD, was prepared and characterized before and after lyophilization. The size distribution of Tf-PLPD was in the range of 240 +/- 12 nm and the zeta potential was -24.10 +/- 2.5 mV. The transfection efficiencies of PLPD and Tf-PLPD were 12.18 +/- 3.8 and 24.26 +/- 2.6 mU beta-galactosidase/mg protein respectively. The lyophilization and the presence of serum didn't affect the tansfectivities of PLPD or Tf-PLPD. Compared to Lipofectamine 2000 (Invitrogen, U.S.A.), the procationic liposomes had less cytotoxicity to cells. In summary the procationic lipoplex described here, combining the condensing effect of protamine and the targeting capability of Tf, was a perspective non-viral vector for gene delivery system.

The application of conventional cationic liposomes/DNA complexes in gene transfer was hampered due to their large size, instability, and limited transfection site in vivo. In this report, we described a dialysis-based method and produced small, stable, and negatively charged DNA-containing liposomes composed of low content of cationic lipid and high content of fusogenic lipid. The liposomes were relatively spherical with a condensed core inside, and exhibited small size with narrow particle size distribution. The encapsulation efficiency of the liposomes was 42.53 +/- 2.29%. They were stable and showed enough protective ability to plasmid DNA from degradation after incubation with different amounts of DNase. Twenty-fold higher transfection efficiency for the liposomes was achieved when compared with that of naked plasmid DNA and no toxicities to hepatocellular carcinoma cells were observed. Our results indicate that the negatively charged DNA-containing liposomes can facilitate gene transfer in cultured cells, and may alleviate the drawbacks of the conventional cationic liposomes/DNA complexes for gene delivery in vivo.

Objective: To prepare plasmid DNA-containing liposomes using detergent removal method and investigate the properties of liposomes., Methods: Using soybean phospholipid and DDAB as lipid materials and Myrj53 as surface modified material, we prepared liposomes by means of detergent removal technique. The shape, size and zeta potential of the liposomes were characterized by TEM and laser particle size analyzer, respectively. The encapsulation efficiency was also investigated. The ability of liposomes to protect the plasmid DNA from degradation was investigated through incubation with DNase I for different time., Results: The liposomes were relatively and regularly spherical in shape and had an average size of 72.73 +/- 7.14 (n = 3) nm with the polydispersity index of 0.288+/-0.093 (n = 3). The zeta potential of the liposomes was -23.77+/- 3.51 (n = 3) mV. The encapsulation efficiency of DNA reached 88.13% +/- 4.41% (n = 3). Liposomes could provide DNA with enough protection from degradation by DNase I ., Conclusion: Detergent removal method is effective and practicable for preparing small-sized plasmid DNA-containing liposomes.

A novel strategy to prepare negatively charged and small DNA-containing liposomes after condensation of plasmid DNA by a cationic lipid in deoxycholate micelle environment is described. The average diameter of resulting complexes was 62 +/- 8 nm. DNA-containing liposomes were then prepared by dialysis. The shape of the resulting liposomes was spherical. The average diameter and the surface charge of the liposomes were 86 +/- 6 nm and -24 +/- 3 mV, respectively. The plasmid DNA inside liposomes remained in a supercoiled form after incubation with DNase.

In the present study, LPDs composing of a series of novel synthetic cholesterylated derivatives bearing a cluster of galactose residues and different spacer lengths were prepared for performing target gene delivery to hepatocytes and their physiochemical properties as well as gene transfer efficiency were investigated. In agreement with the “clustering effect” known to occur with more complex oligomeric structures, the addition of galactose residues under optimized spatial arrangement condition invariably increased the transfect efficiency into hepatoma cells, which can be owed to the sufficient binding of galactose ligands to the ASGPR on hepatocytes. However, the gene transfer ability to hepatocytes was not always improved with extended spacer arms, suggesting a spatial binding sites arrangement of the receptor. Moreover, our research has established galactosylated LPDs, specifically, LPDIIb, LPDIIIc, and LPDIVe as potential vectors to deliver special genes into hepatocytes with low toxicity, combining the condensing effect of protamine and the targeting capability of cholesterylated thiogalactosides. [ABSTRACT FROM AUTHOR]

Objective: In order to prolong the duration of drug in the circulation, multivesicular liposome (MVL, namely DepoFoam™) was utilized as a sustained-release delivery system for hydroxycamptothecin (HCPT). Methods: HCPT is insoluble in both water and physiological acceptable organic solvents; therefore, HCPT–phospholipid complex (HCPT–PCC) was prepared by solvent evaporation method to improve its liposolubility. In this study, preparation, characterization, in vitro release, and in vivo pharmacokinetics of HCPT–phospholipid complex-loaded MVLs (HCPT-MVLs) were investigated. Results: The results showed that the average particle size of HCPT-MVL was 9 μm and the encapsulation efficiency was 90%. In addition, HCPT-MVLs could improve both in vitro release and in vivo pharmacokinetic behaviors of the original drug, with a sustained release of drugs over 5–6 days. Conclusion: These data suggested that by combined use of DepoFoam™ and phospholipid complex formation technique HCPT could be successfully entrapped into the MVLs, which might provide a paradigm for sustained release of insoluble drugs. [ABSTRACT FROM AUTHOR]

Procationic-liposome-protamine-DNA (PLPD) vector, a novel nonviral gene delivery system, that may further adsorb transferrin (Tf) at its surface via electrostatic interactions to form Tf-PLPD, was prepared from soybean phosphatidylcholine (PC), cholesterol (Chol), and a kind of cholesterol derivative, CHETA(cholest-5-en-3-ol(3β)-[2-[[4-[(carboxymethyl)dithio]-1-iminobutyl] amino] ethyl] carba- mate) containing disulfide bond by film dispersion-filteration method. Central composite design was used to optimize the formulation. The presence of serum did not affect the transfection activity of PLPD or Tf-PLPD and the cell viability was not affected significantly when the cells were incubated with the complexes for 4 hr at 37°C. Compared with one kind of cationic liposomes(liposome-protamine-DNA), the PLPD had much less cytotoxicity to three hepar cell lines(including HepG2, SMMC7721, and Chang's normal heptocyte). The procationic lipoplex described here, combining the condensing effect of protamine and the targeting capability of Tf, was a perspective nonviral vector for gene delivery system. [ABSTRACT FROM AUTHOR]